BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 16193074)

  • 1. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.
    Seftel A
    Int J Impot Res; 2007; 19(1):2-24. PubMed ID: 16193074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
    Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new testosterone gel (fortesta) for hypogonadism.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testim 1% testosterone gel for the treatment of male hypogonadism.
    Bouloux P
    Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW; Wyllie MG
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone therapy in men.
    Theodoraki A; Bouloux PM
    Menopause Int; 2009 Jun; 15(2):87-92. PubMed ID: 19465676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy: current trends and future directions.
    Nieschlag E; Behre HM; Bouchard P; Corrales JJ; Jones TH; Stalla GK; Webb SM; Wu FC
    Hum Reprod Update; 2004; 10(5):409-19. PubMed ID: 15297434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
    Asscheman H; Gooren LJ
    Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
    Miner M; Canty DJ; Shabsigh R
    Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy for the primary care physician.
    Casey RW; Barkin J
    Can J Urol; 2008 Aug; 15 Suppl 1():71-7; discussion 77. PubMed ID: 18700068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring androgen replacement therapy: testosterone and prostate safety.
    Morales A
    J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone replacement therapy in male late onset hypogonadism: available pharmacological strategies.
    Turchi P; Simi S; Pescatori ES
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):61-8. PubMed ID: 16760628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.